Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ959MR)

This product GTTS-WQ959MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ959MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1446MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ3439MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ1856MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ7034MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ6890MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ4472MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ91MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ3026MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW